Abstract

Safinamide is a new generation treatment agent (multimodal drug) with different effects than classical monoamine oxidase (MAO)-B inhibitors. It is used together with levodopa or dopamine agonists in the treatment of Parkinson’s disease. While 100 mg of safinamide corresponds to 150 mg of levodopa equivalent dose, 1 mg of rasagiline corresponds to 100 mg of levodopa. In addition to motor problems such as end-of-dose deterioration in Parkinson’s disease, it has positive effects on nonmotor symptoms and daily living activities. It has been used in the USA and many European countries for many years. It has been available to patients in Türkiye since 2024. In this review, the properties of safinamide and clinical study results are presented in light of current literature.